TAPET, a genetically-altered bacteria that has been shown to inhibit tumor growth, will be the focus of a joint study by Vion Pharmaceuticals and Memorial Sloan-Kettering Cancer Center. The New Haven, CT-based company and the New York City-based hospital received a $141,000 research contract from the National Cancer Institute for the preliminary investigation of TAPET-based tumor diagnostic imaging in pre-clinical animal models, according to Vion.
At this stage, the group has not determined what kind of imaging systems will be used in conjunction with TAPET, said Thomas Klein, CFO and vice-president of finance of Vion. Part of the investigation will focus on why the preferential accumulation of TAPET vectors occurs in tumors, said Alan Kessman, president and CEO of Vion.
By AuntMinnie.com staff writers
August 10, 2000
Copyright © 2000 AuntMinnie.com
